Quantcast

Latest Avastin Stories

2014-06-26 12:27:15

LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Colorectal Cancer -- KOL Insight Modulehttp://www.reportbuyer.com/pharma_healthcare/diseases/colorectal_cancer_kol_insight_module.html IntroductionThe global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift due to wider generic competition in cytotoxics and increasing adoption of anti-EGFR products as first line therapies. What will be the impact on market leader...

2014-05-31 16:20:13

Single agent NKTR-102 exceeds primary endpoint with fifty-five percent of patients achieving six-week progression-free survival and fifteen percent of patients achieving partial response SAN FRANCISCO, May 31, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute under the direction of...

2014-05-31 08:21:10

Study Shows Improved Survival Benefit in Panitumumab Arm THOUSAND OAKS, Calif., May 31, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix(®)) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin(®)) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC). The...

2014-04-03 12:30:35

LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth SummaryGBI Research, has released the pharma report "Monoclonal...

2014-02-11 08:33:10

CAMBRIDGE, Mass., Feb. 11, 2014 /PRNewswire/ -- Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in an open label single-arm Phase 2 clinical trial of its lead candidate, CRLX101, in combination with Avastin (bevacizumab) in patients with relapsed ovarian cancer. The Phase 2 combination therapy trial of this investigational treatment is being conducted at Massachusetts General Hospital (MGH) and...

2013-12-30 08:26:41

LONDON, Dec. 30, 2013 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Colorectal Cancer -- KOL Insight Module IntroductionThe global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift due to wider generic competition in cytotoxics and increasing adoption of anti-EGFR products as first line therapies. What will be the impact on market leader Roche/Genetech's Avastin and how do leading clinicians view the changes? The main drivers...

2013-12-10 23:20:12

Reportbuyer.com just published a new market research report: Biosimilar Opportunities in an Evolving Market. London (PRWEB) December 10, 2013 Biosimilars: another milestone passed At the end of June 2013, the European Medicines Agency’s Committee for Medical Products for Human Use issued a positive opinion for the first biosimilar version of Johnson & Johnson’s infliximab for the treatment of rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. For the two...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.